Biologic treatments have modified the therapeutic armamentarium in the treatment of many
dermatological and non- dermatological diseases and data on literature have widely focused on the
efficacy and safety of TNF-alpha inhibitors in psoriasis.
Although the etiopathogenesis has not completely elucidated, inflammation appears the lait motif
unifying the immune-pathogenesis of diverse skin disease, as atopic dermatitis, alopecia areata and
Actually, data on the off-label use of biologics in cutaneous immune-mediated inflammatory diseases
are scarce and restricted to anecdotal cases and case series.
The present review aims to evidence the major off- label use of TNF-alpha inhibitors in dermatology.